The FY17 JPC-2/MIDRP ARA seeks to fund applied research applications focused on the reduction of combat-related or trauma-induced wound infection morbidity and mortality. These projects are expected to inform and identify which potential health products, approaches, or technologies are best positioned for human testing. The intent of the FY17 JPC-2/MIDRP ARA is to support the following: Hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models; Refinement of concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products; Evaluation, maturation, and/or down-selection of potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo; and Completion of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications. Awards may support studies involving human subjects but not clinical trials.
For more information and to apply, visit: http://cdmrp.army.mil/funding/dmrdp.shtml.